Loading stock data…
$13.50-0.06 (-0.44%)
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Bioventus Inc. in the Healthcare sector is trading at $13.52 with a market capitalization of $961M. Wall Street consensus targets $17.60 (5 analysts), implying a +30.2% move over the next 12 months. The stock is currently 15% below its 52-week high of $15.89, remaining 28.6% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $153.21M↑ | $132.09M↓ | $157.90M↑ | $138.65M↓ | $147.66M |
| Gross Profit | $105.67M↑ | $90.77M↓ | $108.78M↑ | $94.23M↓ | $102.09M |
| Operating Income | $18.71M↑ | $8.87M↓ | $21.72M↑ | $11.25M↓ | $18.37M |
| Net Income | $33.44M↑ | $3.11M↓ | $14.76M↑ | $3.15M↓ | $7.46M |
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular an...